Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HNF4A | P41235 | 2/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291923 | 0.92 | CHEK1 (0.50) | CHEK1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL4295657 | 0.88 | CHEK1 (0.52) | CHEK1 | |
| SCHEMBL4295756 | 0.88 | CHEK1 (0.51) | CHEK1 | |
| SCHEMBL4297118 | 0.87 | ACMSD (0.49) | CHEK1DHODHACMSD | |
| SCHEMBL4297039 | 0.87 | DHODH (0.48) | CHEK1DHODHKDM4E | |
| SCHEMBL4300340 | 0.87 | CHEK1 (0.69) | CHEK1DHODH | |
| SCHEMBL4289731 | 0.87 | CHEK1 (0.64) | CHEK1 | |
| SCHEMBL5025815 | 0.86 | KDM4E (0.51) | CHEK1KDM4E | |
| SCHEMBL4294478 | 0.84 | KMT2A (0.48) | CHEK1DHODHKDM4ENPC1 | |
| SCHEMBL4296270 | 0.84 | ACMSD (0.47) | CHEK1ACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885GRIN2D 4593/4885GRIN2A 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.